Integrum AB (publ)

OM:INTEG B Stock Report

Market Cap: SEK 351.1m

Integrum Valuation

Is INTEG B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of INTEG B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate INTEG B's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate INTEG B's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INTEG B?

Key metric: As INTEG B is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for INTEG B. This is calculated by dividing INTEG B's market cap by their current revenue.
What is INTEG B's PS Ratio?
PS Ratio3.3x
SalesSEK 104.53m
Market CapSEK 351.08m

Price to Sales Ratio vs Peers

How does INTEG B's PS Ratio compare to its peers?

The above table shows the PS ratio for INTEG B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average15.5x
BRAIN BrainCool
8.1xn/aSEK 327.9m
BOUL Boule Diagnostics
0.6x6.2%SEK 339.4m
NANEXA Nanexa
6.1x-79.8%SEK 309.4m
ACARIX Acarix
47.2x109.8%SEK 268.1m
INTEG B Integrum
3.3x28.3%SEK 348.2m

Price-To-Sales vs Peers: INTEG B is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (15.5x).

Price to Sales Ratio vs Industry

How does INTEG B's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

15 CompaniesPrice / SalesEstimated GrowthMarket Cap
EKTA B Elekta
1.4x6.8%US$2.14b
ARJO B Arjo
0.9x3.5%US$894.29m
CARE Careium
0.8x10.2%US$62.41m
ADDV A ADDvise Group
0.9x9.2%US$60.08m
INTEG B 3.3xIndustry Avg. 5.0xNo. of Companies15PS0612182430+
15 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: INTEG B is good value based on its Price-To-Sales Ratio (3.3x) compared to the Swedish Medical Equipment industry average (5x).

Price to Sales Ratio vs Fair Ratio

What is INTEG B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INTEG B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ratio7.3x

Price-To-Sales vs Fair Ratio: INTEG B is good value based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (7.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst INTEG B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 17.95
SEK 40.25
+124.2%
8.1%SEK 43.50SEK 37.00n/a2
Jan ’26SEK 18.30
SEK 40.25
+119.9%
8.1%SEK 43.50SEK 37.00n/a2
Dec ’25SEK 21.30
SEK 62.50
+193.4%
15.2%SEK 72.00SEK 53.00n/a2
Nov ’25SEK 25.50
SEK 62.50
+145.1%
15.2%SEK 72.00SEK 53.00n/a2
Oct ’25SEK 26.40
SEK 62.50
+136.7%
15.2%SEK 72.00SEK 53.00n/a2
Sep ’25SEK 31.60
SEK 62.50
+97.8%
15.2%SEK 72.00SEK 53.00n/a2
Aug ’25SEK 50.40
SEK 76.75
+52.3%
2.9%SEK 79.00SEK 74.50n/a2
Jul ’25SEK 57.40
SEK 76.75
+33.7%
2.9%SEK 79.00SEK 74.50n/a2
Jun ’25SEK 50.80
SEK 70.75
+39.3%
5.3%SEK 74.50SEK 67.00n/a2
May ’25SEK 57.20
SEK 70.75
+23.7%
5.3%SEK 74.50SEK 67.00n/a2
Analyst Price Target
Consensus Narrative from 2 Analysts
SEK 40.25
Fair Value
55.4% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 20:47
End of Day Share Price 2025/01/10 00:00
Earnings2024/10/31
Annual Earnings2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Integrum AB (publ) is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerCarnegie Commissioned Research
Oscar BergmanRedeye